Clinical Trial Update: A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety study comparing tapentadol prolonged-release with oxycodone controlled-release in adults with chronic pain, including osteoarthritis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lower Back Pain
• Osteoarthritis of the Hip
• Osteoarthritis of the Knee

Drugs mentioned

• Oxycodone (controlled-release) (oxycodone)
• Tapentadol Prolonged-Release (CG5503) (tapentadol)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Osteoarthritis, Hip, Osteoarthritis, Knee | Phase 3 | Status: COMPLETED | Results posted: 2009-09-04